FY2025 · ended Dec 31, 2025 · Revenue $213.65M, -6.5% YoY · Filed Mar 2, 2026
Amarin Corp Plc\uk (AMRN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $213.6 million and a net loss of $38.8 million. As of Sep 30, 2026 it held $323.4 million in cash and investments and $7.6 million in total debt.
Revenue (TTM)
$176.11M
-22.3% vs year-ago TTM
Net income (TTM)
$-19.14M
+77.8% vs year-ago TTM
Operating cash flow (TTM)
$37.49M
+271.5% vs year-ago TTM
Free cash flow
$-22.00M
-85.7% vs prior year
EPS (TTM)
$-0.05
+78.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
416.21M
+1.1% vs prior year
Net cash
$315.78M
as of Sep 30, 2026
Operating margin
-18.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Dublin 2
- SEC filer status
- Accelerated filer
- SEC CIK
- 897448
- Former names
- AMARIN CORP PLC\UK (until Oct 28, 2026); AMARIN PHARMACEUTICALS PLC (until Jul 13, 2000); ETHICAL HOLDINGS PLC (until Jan 28, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $213.6M | $228.6M | $306.9M | $369.2M | $583.2M |
| Operating income | -$50.2M | -$91.8M | -$67.6M | -$105.9M | $10.5M |
| Net income | -$38.8M | -$82.2M | -$59.1M | -$105.8M | $7.7M |
| Diluted EPS | -$0.09 | -$0.20 | -$0.15 | -$0.26 | $0.02 |
| Operating cash flow | $6.7M | -$31.0M | $6.9M | -$180.1M | -$66.5M |
| Total assets | $670.8M | $685.3M | $831.7M | $886.2M | $1.1B |
| Total liabilities | $211.5M | $199.2M | $279.6M | $290.8M | $401.0M |
| Stockholders' equity | $459.3M | $486.2M | $552.1M | $595.3M | $667.1M |
| Cash and investments | $302.6M | $294.2M | $320.7M | $310.6M | $489.1M |
| Total debt | $8.2M | $9.7M | $10.6M | $11.6M | $10.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 15, 2026 | May 13, 2026 |
| 10-Q | Quarterly report | Apr 29, 2026 | Mar 31, 2026 |
All 1003 Amarin Corp Plc\uk SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.